Haas Kevin Richard 4

What Happened
Kevin Richard Haas, Chief Technology Officer of Myriad Genetics (MYGN), was awarded 23,697 performance-based restricted stock units (PSUs) on February 2, 2026. The award was reported on a Form 4 filed February 3, 2026. The PSUs were granted at $0.00 (they are awards, not purchases) and represent contingent rights to receive one share of common stock each upon vesting.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 3, 2026 (timely filing).
• Transaction type/code: Award/Grant (A). Price reported: $0.00. Total reported acquisition value: $0.
• Shares granted: 23,697 performance-based restricted stock units (PSUs).
• Vesting/conversion: Each PSU converts to one share and vests on March 15, 2026, subject to final certification of performance metrics.
• Footnote: The Compensation and Human Capital Committee determined the final award amount based on achievement of pre-determined performance metrics (see footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.

Context
PSUs are a form of equity compensation tied to performance goals; they are not open-market purchases or sales and carry no immediate cash consideration (hence $0 acquisition price). If performance targets remain met, the PSUs will convert to common shares on the stated vesting date. Awards like this reflect company compensation decisions rather than direct insider buying or selling activity.